Last year was a banner year for US cell and gene therapy manufacturers, with FDA approvals of two CAR T cell therapies
Last year was a banner year for US cell and gene therapy manufacturers, with FDA approvals of two CAR T cell therapies and an in vivo gene therapy. Industry is working hard to solve the challenges associated with commercializing these exciting products.
MIT\’s Center for Biomedical Innovation BioMAN Program will host a 2-day Summit that explores the lessons learned from these recent product approvals and the critical role technology innovation plays in insuring that these important biologic medicines reach the patients who need them.
The 2018 BioMAN Summit will bring together thought leaders from industry, academia, and government for a series of invited presentation and panel discussions that will:
december 11 (Tuesday) - 12 (Wednesday)